Literature DB >> 23398121

Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer.

Yu Zheng1, Angela L Tyner.   

Abstract

BACKGROUND: Protein tyrosine kinase 6 (PTK6) is an intracellular tyrosine kinase that is distantly related to SRC family kinases. PTK6 is nuclear in normal prostate epithelia, but nuclear localization is lost in prostate tumours. Increased expression of PTK6 is detected in human prostate cancer, especially at metastatic stages, and in other types of cancers, including breast, colon, head and neck cancers, and serous carcinoma of the ovary.
MATERIALS AND METHODS: Potential novel substrates of PTK6 identified by mass spectrometry were validated in vitro. The significance of PTK6-induced phosphorylation of these substrates was addressed using human prostate cell lines by knockdown of endogenous PTK6 or overexpression of targeted PTK6 to different intracellular compartments.
RESULTS: We identified AKT, p130CAS and focal adhesion kinase (FAK) as novel PTK6 substrates and demonstrated their roles in promoting cell proliferation, migration and resistance to anoikis. In prostate cancer cells, active PTK6 is primarily associated with membrane compartments, although the majority of total PTK6 is localized within the cytoplasm. Ectopic expression of membrane-targeted PTK6 transforms immortalized fibroblasts. Knockdown of endogenous cytoplasmic PTK6 in PC3 prostate cancer cells impairs proliferation, migration and anoikis resistance. However, re-introduction of PTK6 into the nucleus significantly decreases cell proliferation, suggesting context-specific functions for nuclear PTK6.
CONCLUSIONS: In human prostate cancer, elevated PTK6 expression, translocation of PTK6 from the nucleus to the cytoplasm and its activation at the plasma membrane contribute to increased phosphorylation and activation of its substrates such as AKT, p130CAS and FAK, thereby promoting prostate cancer progression.
© 2013 The Authors. European Journal of Clinical Investigation © 2013 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23398121      PMCID: PMC3602132          DOI: 10.1111/eci.12050

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  68 in total

1.  Regulation of Akt/PKB activation by tyrosine phosphorylation.

Authors:  R Chen; O Kim; J Yang; K Sato; K M Eisenmann; J McCarthy; H Chen; Y Qiu
Journal:  J Biol Chem       Date:  2001-07-09       Impact factor: 5.157

Review 2.  Cell migration: integrating signals from front to back.

Authors:  Anne J Ridley; Martin A Schwartz; Keith Burridge; Richard A Firtel; Mark H Ginsberg; Gary Borisy; J Thomas Parsons; Alan Rick Horwitz
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

3.  Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling.

Authors:  Egle Avizienyte; Anne W Wyke; Robert J Jones; Gordon W McLean; M Andrew Westhoff; Valerie G Brunton; Margaret C Frame
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

4.  Identification of tyrosine kinases overexpressed in head and neck cancer.

Authors:  Ho-Sheng Lin; Gerald J Berry; Willard E Fee; David J Terris; Zijie Sun
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-03

5.  Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma.

Authors:  Stephanie Ma; Jessie Y J Bao; Pak Shing Kwan; Yuen Piu Chan; Carol M Tong; Li Fu; Na Zhang; Amy H Y Tong; Yan-Ru Qin; Sai Wah Tsao; Kwok Wah Chan; Si Lok; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2012-06-13       Impact factor: 22.682

6.  Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.

Authors:  Jason J Derry; Gail S Prins; Vera Ray; Angela L Tyner
Journal:  Oncogene       Date:  2003-07-03       Impact factor: 9.867

7.  Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.

Authors:  Shin-Ae Kang; Hyun-Soo Cho; Jong Bok Yoon; In Kwon Chung; Seung-Taek Lee
Journal:  Biochem J       Date:  2012-10-15       Impact factor: 3.857

Review 8.  Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases.

Authors:  Michael S Serfas; Angela L Tyner
Journal:  Oncol Res       Date:  2003       Impact factor: 5.574

9.  Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.

Authors:  X Li; Y Lu; K Liang; J-M Hsu; C Albarracin; G B Mills; M-C Hung; Z Fan
Journal:  Oncogene       Date:  2012-01-09       Impact factor: 9.867

10.  A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations.

Authors:  Tao Xie; Giovanni D' Ario; John R Lamb; Eric Martin; Kai Wang; Sabine Tejpar; Mauro Delorenzi; Fred T Bosman; Arnaud D Roth; Pu Yan; Stephanie Bougel; Antonio Fabio Di Narzo; Vlad Popovici; Eva Budinská; Mao Mao; Scott L Weinrich; Paul A Rejto; J Graeme Hodgson
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

View more
  20 in total

1.  Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.

Authors:  Tiffany Tsui; W Todd Miller
Journal:  Biochemistry       Date:  2015-05-13       Impact factor: 3.162

2.  Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells.

Authors:  Darren J Wozniak; Ben Hitchinson; Milica B Gilic; Wenjun Bie; Vadim Gaponenko; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

3.  Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.

Authors:  Priya S Mathur; Jessica J Gierut; Grace Guzman; Hui Xie; Rosa M Xicola; Xavier Llor; Michael I Chastkofsky; Ansu O Perekatt; Angela L Tyner
Journal:  Mol Cancer Res       Date:  2016-03-16       Impact factor: 5.852

4.  PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer.

Authors:  Yu Zheng; Zebin Wang; Wenjun Bie; Patrick M Brauer; Bethany E Perez White; Jing Li; Veronique Nogueira; Pradip Raychaudhuri; Nissim Hay; Debra A Tonetti; Virgilia Macias; André Kajdacsy-Balla; Angela L Tyner
Journal:  Cancer Res       Date:  2013-07-15       Impact factor: 12.701

5.  PTK6 promotes hepatocellular carcinoma cell proliferation and invasion.

Authors:  Xiaohong Chen; Bo Song; Yuanlong Lin; Lijun Cao; Shiyan Feng; Lin Zhang; Fuxiang Wang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 6.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

Review 7.  Protein tyrosine kinase 6 signaling in prostate cancer.

Authors:  Wanian M Alwanian; Angela L Tyner
Journal:  Am J Clin Exp Urol       Date:  2020-02-25

8.  Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.

Authors:  Amy R Dwyer; Carlos Perez Kerkvliet; Raisa I Krutilina; Hilaire C Playa; Tiffany N Seagroves; Carol A Lange; Deanna N Parke; Warner A Thomas; Branden A Smeester; Branden S Moriarity
Journal:  Mol Cancer Res       Date:  2020-11-10       Impact factor: 6.333

9.  Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.

Authors:  Michael I Chastkofsky; Wenjun Bie; Susan M Ball-Kell; Yu-Ying He; Angela L Tyner
Journal:  J Invest Dermatol       Date:  2015-04-30       Impact factor: 8.551

10.  Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.

Authors:  M Peng; S M Ball-Kell; R R Franks; H Xie; A L Tyner
Journal:  Oncogenesis       Date:  2013-12-09       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.